Published in Rheum Dis Clin North Am on May 01, 2010
Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest (2012) 1.72
Homocysteine suppresses the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation. J Biol Chem (2010) 1.12
Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest (2011) 1.05
Celastrus and its bioactive celastrol protect against bone damage in autoimmune arthritis by modulating osteoimmune cross-talk. J Biol Chem (2012) 1.01
Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis. J Biol Chem (2012) 0.94
Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways. PLoS One (2013) 0.91
Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE(2), and MMP-13 expression. Acta Pharmacol Sin (2013) 0.90
Investigate pathogenic mechanism of TXNDC5 in rheumatoid arthritis. PLoS One (2013) 0.89
Osteoimmunology: a brief introduction. Immune Netw (2013) 0.89
Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective. Int J Med Sci (2012) 0.88
Carbonic anhydrase I (CA1) is involved in the process of bone formation and is susceptible to ankylosing spondylitis. Arthritis Res Ther (2012) 0.88
Production of RANKL by Memory B Cells: A Link Between B Cells and Bone Erosion in Rheumatoid Arthritis. Arthritis Rheumatol (2016) 0.83
Leptin induces oncostatin M production in osteoblasts by downregulating miR-93 through the Akt signaling pathway. Int J Mol Sci (2014) 0.82
Bone formation and resorption are both increased in experimental autoimmune arthritis. PLoS One (2012) 0.81
Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats. PLoS One (2015) 0.80
Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases. Biomed Res Int (2014) 0.80
CCN1 induces oncostatin M production in osteoblasts via integrin-dependent signal pathways. PLoS One (2014) 0.80
Inhomogeneity of immune cell composition in the synovial sublining: linear mixed modelling indicates differences in distribution and spatial decline of CD68+ macrophages in osteoarthritis and rheumatoid arthritis. Arthritis Res Ther (2016) 0.79
Periarticular bone loss in antigen-induced arthritis. Arthritis Rheum (2013) 0.79
CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response. Clin Exp Immunol (2014) 0.79
Alexithymia, mood states and pain experience in systemic lupus erythematosus and rheumatoid arthritis. Clin Rheumatol (2014) 0.79
The osteoclast--what's new? Skeletal Radiol (2011) 0.78
Tofacitinib prevents radiographic progression in rheumatoid arthritis. J Korean Med Sci (2013) 0.78
Norisoboldine, an Anti-Arthritis Alkaloid Isolated from Radix Linderae, Attenuates Osteoclast Differentiation and Inflammatory Bone Erosion in an Aryl Hydrocarbon Receptor-Dependent Manner. Int J Biol Sci (2015) 0.78
[Inflammation and bone : Osteoimmunological aspects]. Z Rheumatol (2016) 0.77
Cross-talk between T cells and osteoclasts in bone resorption. Bonekey Rep (2012) 0.77
The study of mechanisms of protective effect of Rg1 against arthritis by inhibiting osteoclast differentiation and maturation in CIA mice. Mediators Inflamm (2014) 0.77
FOXO1 deletion reduces dendritic cell function and enhances susceptibility to periodontitis. Am J Pathol (2015) 0.77
Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis. BMC Musculoskelet Disord (2014) 0.75
Margaritaria discoidea (Euphorbiaceae) stem bark extract attenuates allergy and Freund's adjuvant-induced arthritis in rodents. Pharmacognosy Res (2014) 0.75
Increased risk of vertebral fracture in patients with rheumatoid arthritis: A meta-analysis. Medicine (Baltimore) (2016) 0.75
Body composition in patients with rheumatoid arthritis is not different than healthy subjects. Eur J Rheumatol (2014) 0.75
Osteoimmunology and Beyond. Curr Med Chem (2016) 0.75
Protective effects of Fructus sophorae extract on collagen-induced arthritis in BALB/c mice. Exp Ther Med (2016) 0.75
Osteoclast-Primed Foxp3+ CD8 T Cells Induce T-bet, Eomesodermin, and IFN-γ To Regulate Bone Resorption. J Immunol (2016) 0.75
Surgical Debridement Is Superior to Sole Antibiotic Therapy in a Novel Murine Posttraumatic Osteomyelitis Model. PLoS One (2016) 0.75
Anti-rheumatoid Activity of Secondary Metabolites Produced by Endophytic Chaetomium globosum. Front Microbiol (2016) 0.75
1,25-Dihydroxyvitamin D3 prevents bone loss of the secondary spongiosa in arthritic rats by an increase of bone formation and mineralization and inhibition of bone resorption. BMC Musculoskelet Disord (2014) 0.75
Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats. Pharmacol Res Perspect (2015) 0.75
Herbal formula Xian-Fang-Huo-Ming-Yin regulates differentiation of lymphocytes and production of pro-inflammatory cytokines in collagen-induced arthritis mice. BMC Complement Altern Med (2017) 0.75
The degree of cartilage degradation assessed by serum biomarker levels changes after arthroscopic knee synovectomy in rheumatoid arthritis patients. Int Orthop (2017) 0.75
Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT). Arthritis Res Ther (2017) 0.75
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J (1991) 8.31
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet (2004) 7.90
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (2008) 7.37
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis (2008) 6.97
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum (1999) 6.39
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest (2000) 5.78
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A (2003) 5.09
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum (2006) 4.61
Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum (2004) 4.58
Matrix metalloproteinases: role in arthritis. Front Biosci (2006) 4.52
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med (2000) 4.06
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum (2008) 4.02
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis (2010) 3.90
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem (2005) 3.88
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 3.78
IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest (2005) 3.56
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol (2001) 3.53
Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum (2000) 3.51
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res (1998) 2.72
Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol (1998) 2.68
Identification of radiologic healing phenomena in patients with rheumatoid arthritis. J Rheumatol (2001) 2.54
Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest (1993) 2.52
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol (2005) 2.40
Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A (1998) 2.37
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 2.35
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis (2008) 2.35
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol (2005) 2.26
Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology (2000) 2.13
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum (2008) 2.07
Bone stem cells. J Cell Biochem Suppl (1998) 2.02
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2008) 2.02
Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum (1998) 2.01
Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem (2001) 1.99
Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum (2004) 1.94
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum (2004) 1.94
IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine (2007) 1.93
Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum (1984) 1.85
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res (2004) 1.83
Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol (1992) 1.83
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum (2000) 1.79
IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol (2003) 1.78
IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol (1990) 1.77
Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem (2006) 1.73
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum (2006) 1.73
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum (2008) 1.73
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res (2009) 1.68
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum (1997) 1.60
The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res (2001) 1.57
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum (2004) 1.53
The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol (2008) 1.52
Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis (2009) 1.51
Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw (1996) 1.47
RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res (2003) 1.46
Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum (2009) 1.40
Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology (2004) 1.39
Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) (2002) 1.38
Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) (2002) 1.37
Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum (2004) 1.37
Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum (2010) 1.35
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis (2013) 3.25
Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum (2007) 3.23
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med (2004) 2.19
Rheumatic diseases: the effects of inflammation on bone. Immunol Rev (2005) 2.07
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology (2011) 1.87
End-to-end electronic control of the hospital transfusion process to increase the safety of blood transfusion: strengths and weaknesses. Transfusion (2006) 1.71
Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res (2009) 1.68
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis (2010) 1.53
Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum (2002) 1.50
Bone remodeling in rheumatic disease: a question of balance. Immunol Rev (2010) 1.42
GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res (2002) 1.38
Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum (2002) 1.34
A novel role for GADD45beta as a mediator of MMP-13 gene expression during chondrocyte terminal differentiation. J Biol Chem (2005) 1.30
Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) (2012) 1.28
The rise of cholesterol testing: how much is unnecessary. Br J Gen Pract (2011) 1.27
Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol (2011) 1.23
The advent of biosimilar therapies in rheumatology--"O brave new world". Nat Rev Rheumatol (2012) 1.22
Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther (2014) 1.10
Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum (2003) 1.08
Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum (2012) 1.08
The Ets transcription factor ESE-1 mediates induction of the COX-2 gene by LPS in monocytes. FEBS J (2005) 1.06
Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol (2004) 1.05
ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation. J Biol Chem (2004) 1.01
Rituximab biosimilars. Expert Opin Biol Ther (2013) 1.01
Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology (2009) 1.00
Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken) (2011) 0.98
Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol (2012) 0.97
Relapsing polychondritis. Rheum Dis Clin North Am (2013) 0.97
The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum (2009) 0.94
Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis (2013) 0.94
Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep (2002) 0.93
Rheumatic manifestations of diabetes mellitus. Rheum Dis Clin North Am (2010) 0.93
Impact of inflammation on the osteoblast in rheumatic diseases. Curr Osteoporos Rep (2014) 0.92
The role played by cell-substrate interactions in the pathogenesis of osteoclast-mediated peri-implant osteolysis. Arthritis Res Ther (2006) 0.92
Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator. Arthritis Rheum (2009) 0.91
Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum (2002) 0.91
Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population. Clin Chem (2006) 0.88
Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford) (2012) 0.88
Bisphosphonates: environmental protection for the joint? Arthritis Rheum (2004) 0.88
Sensorineural hearing loss following imatinib (Gleevec) administration. Otolaryngol Head Neck Surg (2011) 0.88
Rheumatoid arthritis: Repair of erosion in RA--shifting the balance to formation. Nat Rev Rheumatol (2011) 0.87
Advanced glycation endproducts and osteoarthritis. Curr Rheumatol Rep (2003) 0.86
Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis Rheum (2004) 0.86
Biosimilars: implications for rheumatoid arthritis therapy. Curr Opin Rheumatol (2017) 0.86
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford) (2013) 0.85
A rheumatology-specific informatics-based application with a disease activity calculator. Arthritis Rheum (2009) 0.84
Methotrexate: the gold standard without standardisation. Ann Rheum Dis (2009) 0.83
Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging (2009) 0.82
Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med (2009) 0.82
Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Curr Rheumatol Rep (2008) 0.82
Assessment of control of rheumatoid arthritis disease activity. Best Pract Res Clin Rheumatol (2011) 0.81
Hand bone mineral density is associated with both total hip and lumbar spine bone mineral density in post-menopausal women with RA. Rheumatology (Oxford) (2009) 0.81
Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 0.79
Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther (2016) 0.78
How do we approach a major change program using the example of the development, evaluation, and implementation of an electronic transfusion management system. Transfusion (2009) 0.78
Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis (2010) 0.78
Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep (2008) 0.78
Case records of the Massachusetts General Hospital. Case 37-2009. A 46-year-old woman with chronic renal failure, leg swelling, and skin changes. N Engl J Med (2009) 0.78
Induction of bone loss in DBA/1J mice immunized with citrullinated autologous mouse type II collagen in the absence of adjuvant. Immunol Res (2014) 0.77
Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database. J Clin Rheumatol (2015) 0.77
Entheses and bones in spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol (2009) 0.77
How do we monitor hospital transfusion practice using an end-to-end electronic transfusion management system? Transfusion (2012) 0.77
Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness. N Engl J Med (2006) 0.77
Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol (2013) 0.76
Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med (2008) 0.76
Rheumatoid arthritis: erosion defined: back to basics. Nat Rev Rheumatol (2013) 0.75
Stress-induced cardiomyopathy after patent foramen ovale closure: what role did anesthesia play? J Cardiothorac Vasc Anesth (2012) 0.75
Orthotopic heart transplantation in a patient with corrected L-transposition of great arteries and dextrocardia. J Heart Lung Transplant (2008) 0.75
Erratum to: Treating rheumatoid arthritis to target: an international initiative. Curr Rev Musculoskelet Med (2011) 0.75
Abortion: round 1. Commentary (1994) 0.75
Wegener's granulomatosis: is biologic therapy useful? Curr Rheumatol Rep (2006) 0.75
Nephrogenic systemic fibrosis: a new concern for rheumatologists. Nat Clin Pract Rheumatol (2008) 0.75
Treating rheumatoid arthritis to target: an international initiative. Curr Rev Musculoskelet Med (2011) 0.75
Evaluation of alert-based monitoring in a computerised blood transfusion management system. Stud Health Technol Inform (2011) 0.75
Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken) (2013) 0.75
Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. J Am Acad Dermatol (2011) 0.75
New policy on disclosure of interest for American College of Rheumatology Journals. Arthritis Rheum (2003) 0.75
New policy on disclosure of interest for American College of Rheumatology journals. Arthritis Rheum (2003) 0.75